NasdaqGS - Nasdaq Real Time Price USD

Illumina, Inc. (ILMN)

116.69

-1.60

(-1.35%)

At close: April 18 at 4:00 PM EDT

115.77

-0.92

(-0.79%)

After hours: April 18 at 7:27 PM EDT

Engineering a Cool Career in Biotech - and Volunteering Along the Way

What kind of opportunities can an engineer find through their work? Plenty, at Illumina! One employee shares how she makes a difference. Originally published on Illumina News Center NORTHAMPTON, MA / ACCESSWIRE / April 18, 2024 / Inside a lab that ...

ACCESSWIRE 10 hours ago

ILMN
-1.35%
Evidence Supports Sequencing As First-Line Rare Disease Diagnostic

The Medical Genome Initiative presents a paper in an effort to expand patient access to sequencing Originally published on Illumina News Center NORTHAMPTON, MA / ACCESSWIRE / April 17, 2024 / A recent literature review, published in the Nature journalGenomic ...

ACCESSWIRE yesterday

ILMN
-1.35%
European Commission approves Illumina’s proposed Grail split

Selling Grail to a third party would free Illumina of the need to capitalize the company, but the buyer would need the commission’s approval, analysts wrote.

MedTech Dive 3 days ago

ILMN
-1.35%
Illumina's planned divestment of GRAIL approved by the European Commission

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment plan for GRAIL from the European Commission (EC).

PR Newswire 6 days ago

ILMN
-1.35%
UPDATE 2-EU approves Illumina's plan to divest cancer test maker Grail

U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the deal two years ago. The company said it has reached an agreement with the European Commission on specific divestment options, but the method has not been finalised. Illumina founded Grail and spun it off in 2016, but re-acquired it in 2021 for $7.1 billion to enter the cancer early-detection market, before first securing EU regulatory approval.

Reuters 6 days ago

ILMN
-1.35%
EU approves Illumina's plan to divest cancer test maker Grail

BRUSSELS (Reuters) -U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the deal two years ago. The company said it has reached an agreement with the European Commission on specific divestment options, but the method has not been finalised. Illumina founded Grail and spun it off in 2016, but re-acquired it in 2021 for $7.1 billion to enter the cancer early-detection market, before first securing EU regulatory approval.

Reuters 6 days ago

ILMN
-1.35%
Search for Cancer Blood Test Continues Despite Illumina-Grail Deal’s Failure

Investors shelved their hopes for a pioneering cancer blood test after Illumina ‘s $8 billion acquisition of start-up Grail was scuttled by antitrust regulators last year. A decade from now, these blood tests could be used to flag the more than 60% of deadly cancers that currently lack any way to screen for them. At the annual meeting of the American Association for Cancer Research in San Diego, Exact Sciences reported on a 6,000-sample study of a multi-cancer test it plans to offer alongside single-cancer screening products such as its well-known Cologuard stool-based test for colon cancer.

Barrons.com 8 days ago

ILMN
-1.35%
EXAS
+0.41%
Illumina CFO steps down amid executive shakeup

Ankur Dhingra, who worked with Illumina’s CEO at Agilent Technologies, is joining the genome sequencing company to replace Joydeep Goswami.

MedTech Dive 9 days ago

ILMN
-1.35%
A
UPDATE 2-Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed

Illumina said on Tuesday Chief Financial Officer Joydeep Goswami will leave the gene sequencing company and be succeeded by former Summit Therapeutics' executive Ankur Dhingra. Goswami, who has more than two decades of experience in the life sciences industry, was the CFO since early 2023 and will serve as an adviser till June 30, the company said. Prior to Summit, Dhingra was the CFO at medical test maker CareDx.

Reuters 9 days ago

ILMN
-1.35%
Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed

Goswami, who has more than two decades of experience in the life sciences industry, was the CFO since early 2023 and will serve as an adviser till June 30, the company said. Prior to Summit, Dhingra was the CFO at medical test maker CareDx. Illumina has also reaffirmed its forecast for the first quarter and full-year 2024.

Reuters 9 days ago

ILMN
-1.35%
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments.

PR Newswire 9 days ago

ILMN
-1.35%
Nasdaq’s Nosebleed Section: 3 Expensive Stocks to Sell Before It’s Too Late

The stock market has been in a solid rally since the third quarter of 2023, pushing significant indices to new highs. That upward trajectory also raised company valuations for many stocks, putting investors at risk of inflated stock prices and selloffs. Being the most traded exchange in the states, the Nasdaq is no stranger to seeing expensive stocks that investors should sell. These expensive stocks show signs of decline or have recently seen explosive price growth that lacks fundamental suppor

InvestorPlace 13 days ago

MDB

ILMN
-1.35%
Why More Clinical Labs Are Turning to Whole-Genome Sequencing for Cancer

NORTHAMPTON, MA / ACCESSWIRE / April 5, 2024 / Illumina The adoption of WGS in precision oncology is on the rise. Plus: the promise of MRD Originally published on Illumina News Center Whole-genome sequencing (WGS) use is more established for rare ...

ACCESSWIRE 13 days ago

ILMN
-1.35%
Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024

Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the first quarter 2024 following the close of market on Thursday, May 2, 2024.

PR Newswire 14 days ago

ILMN
-1.35%
Giving Students a New Window on Genomic Technologies

Illumina Genomic Discoveries helps high school students learn about genomic sequencing with a Lab-in-a-Box NORTHAMPTON, MA / ACCESSWIRE / April 2, 2024 / Illumina Originally published on Illumina News Center Next-generation sequencing (NGS) provides ...

ACCESSWIRE 16 days ago

ILMN
-1.35%
20 Foods To Reduce Cancer Risk

In this article, we will be taking a look at the 2o foods to reduce cancer risk. If you do no want learn about the global and US cancer stats, head straight to the 5 Foods To Reduce Cancer Risk. Global and US Cancer Statistics According to data from the World Cancer Research Fund International, […]

Insider Monkey 19 days ago

ILMN
-1.35%
GH
Is Illumina, Inc. (NASDAQ:ILMN) Trading At A 36% Discount?

Key Insights Illumina's estimated fair value is US$210 based on 2 Stage Free Cash Flow to Equity Illumina's US$134...

Simply Wall St. 22 days ago

ILMN
-1.35%
Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks 23 days ago

ILMN
-1.35%
CI
14 Best Medical Device Stocks To Buy Now

In this article, we will discuss the 14 Best Medical Device Stocks To Buy Now. You can skip our detailed analysis of the Medical Device Industry and go directly to the 5 Best Medical Device Stocks To Buy Now. The healthcare sector relies heavily on advancements in medical technology, which encompasses medical devices aiding in […]

Insider Monkey 23 days ago

ABT

SYK

ILMN
-1.35%
Court adviser sides with Illumina in EU row that triggered Grail fine

Illumina is still planning to divest Grail but may escape a fine of about 432 million euros imposed by the European Commission.

MedTech Dive 24 days ago

ILMN
-1.35%

Performance Overview

Return	ILMN	S&P 500
YTD	-16.20%	+5.06%
1-Year	-49.26%	+20.71%
3-Year	-70.75%	+19.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Illumina, Inc. (ILMN)

Engineering a Cool Career in Biotech - and Volunteering Along the Way

Evidence Supports Sequencing As First-Line Rare Disease Diagnostic

European Commission approves Illumina’s proposed Grail split

Illumina's planned divestment of GRAIL approved by the European Commission

UPDATE 2-EU approves Illumina's plan to divest cancer test maker Grail

EU approves Illumina's plan to divest cancer test maker Grail

Search for Cancer Blood Test Continues Despite Illumina-Grail Deal’s Failure

Illumina CFO steps down amid executive shakeup

UPDATE 2-Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed

Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed

Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

Nasdaq’s Nosebleed Section: 3 Expensive Stocks to Sell Before It’s Too Late

Why More Clinical Labs Are Turning to Whole-Genome Sequencing for Cancer

Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024

Giving Students a New Window on Genomic Technologies

20 Foods To Reduce Cancer Risk

Is Illumina, Inc. (NASDAQ:ILMN) Trading At A 36% Discount?

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

14 Best Medical Device Stocks To Buy Now

Court adviser sides with Illumina in EU row that triggered Grail fine

Performance Overview